431 Results

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Feldman
    Feldman
  4. Antonescu
    Antonescu
  5. Hakimi
    Hakimi
  6. Patil
    Patil
  7. Abou-Alfa
    Abou-Alfa
  8. DeMatteo
    DeMatteo
  9. Ginsberg
    Ginsberg
  10. Reidy
    Reidy

Groups

  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)
  7. Gastrointestinal Oncology Service (41)
  8. Radiology, Department of (38)
  9. Survivorship Research (34)
  10. Tow Center for Developmental Oncology (TCDO) (33)
  1. "sunitinib"
Formats
  1. Journal Article (391)
  2. Review (21)
  3. Editorial (5)
  4. Research Letter (4)
  5. Book Section (3)
  6. Correspondence (3)
  7. Guidelines (3)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)

More Groups

People
  1. Robert Motzer (159)
  2. Martin Voss (24)
  3. Darren Feldman (23)
  4. Robert Maki (20)
  5. Chung-Han Lee (17)
  6. Cristina Antonescu (17)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (18)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Clinical Cancer Research (18)
  3. European Urology (18)
  4. Journal of the National Comprehensive Cancer Network (17)
  5. Cancer (14)
  6. European Journal of Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (69)
  2. Elsevier Science, Inc. (38)
  3. Springer (31)
  4. Wiley Blackwell (30)
  5. Oxford University Press (29)
  6. Nature Publishing Group (27)

More Publishers

Results (431)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 CLEAR study in patients with advanced renal cell carcinoma: Outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Journal Article

    Grünwald, V.; Powles, T.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C.; Motzer, R.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Diagnostic approaches for neuroendocrine neoplasms of unknown primary (NEN-UPs) and their prognostic relevance—A retrospective, long-term single-center experience
    Journal Article

    Schmidt, M.; Hinterleitner, C.; Singer, S.; Lauer, U. M.; Zender, L.; Hinterleitner, M.
    Cancers (2023)

    Fulltext@MSK | Save
  • Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: Analysis of the phase 3 randomized CLEAR Study
    Journal Article

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso-Gordoa, T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    European Urology Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
    Journal Article

    Gelderblom, H.; Jones, R. L.; Blay, J. Y.; George, S.; von Mehren, M.; Zalcberg, J. R.; Kang, Y. K.; Razak, A. A.; Trent, J.; Attia, S.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma
    Journal Article

    McGregor, B.; Geynisman, D. M.; Burotto, M.; Suárez, C.; Bourlon, M. T.; Barata, P. C.; Gulati, S.; Huo, S.; Ejzykowicz, F.; Blum, S. I.; more...
    European Urology Oncology (2023)

    Fulltext@MSK | Save
  • Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
    Journal Article

    Chakiryan, N. H.; Kim, Y.; Berglund, A.; Chang, A.; Kimmel, G. J.; Hajiran, A.; Nguyen, J.; Moran-Segura, C.; Saeed-Vafa, D.; Katende, E. N.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase II trial of sunitinib or cediranib in alveolar soft part sarcoma
    Editorial

    Nguyen, J.; Takebe, N.; Kummar, S.; Razak, A.; Chawla, S. P.; George, S.; Patel, S. R.; Keohan, M. L.; Movva, S.; O'Sullivan Coyne, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Adjuvant therapy options in renal cell carcinoma — Targeting the metastatic cascade
    Review

    Fitzgerald, K. N.; Motzer, R. J.; Lee, C. H.
    Nature Reviews Urology (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save